ClinicalTrials.gg
CompletedNCT01725217Updated Apr 28, 2023Results posted

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia

A Phase 3 interventional study of MenACWY-CRM in Meningococcal Disease, sponsored by Novartis Vaccines. Completed at 4 sites in Russian Federation. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-28.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
198
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Meningococcal Infections by Novartis — none open to participants now, none under way, none of them phase 3. Meningococcal Infections · Novartis.

Enrollment
45th of 57
198 · median 484
Started
2012
with 1 other
Phase 3
27 of 60
none open now
Registered
53rd of 60
by date

Among the 60 studies in Meningococcal Infections by Novartis, this one is the 45th largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2012, is one of 27 in phase 3, and was the 53rd registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

None of the 60 studies in Meningococcal Infections by Novartis is open now. The open studies under Meningococcal Infections, anywhere →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 2 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 60 studies in Meningococcal Infections by Novartis as a file.
02

Study summary

To evaluate the immune response and safety following a single dose of Novartis Meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy children, adolescents and adults in Russia.

03

Conditions studied

  • Meningococcal Disease

Keywords

  • Meningitis
  • children
  • adolescents
  • adults
  • MenACWY
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Individuals eligible for enrollment in this study were those:

  1. Who were of any gender, from the age of 2 years and above at the time of visit 1, and to whom the nature of the study had been described and:

    • the parent/legal representative had provided written (≥2 to \<18 years of age),
    • had provided written assent (≥11 to \<18 years of age),
    • had provided written informed consent (≥18 years of age onwards).
  2. Who the investigator believed that the subject and/or his or her parent/legal representative could and would comply with the requirements of the protocol (e.g., completion of the Diary Card, return for follow-up visit).
  3. Who were in good health as determined by

    • medical history
    • physical exam
    • clinical judgment of the investigator
  4. Who had a negative urine pregnancy test for female subjects from 11 years of age.

Exclusion criteria

Exclusion Criteria:

Individuals not eligible to be enrolled in the study were those:

  1. Who were unwilling or unable to give written informed assent or consent to participate in the study.
  2. Who were perceived to be unreliable or unavailable for the duration of the study period.
  3. Who had a previous confirmed or suspected disease caused by N meningitidis.
  4. Who had household contact with and/or intimate exposure to an individual with culture-proven N meningitidis infection within 60 days prior to enrollment.
  5. Who had previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s) (licensed or ).
  6. Who were pregnant or breast feeding (female subjects).
  7. Who had received any investigational or non-registered product (drug or vaccine) within 28 days prior to enrollment or who expected to receive an investigational drug or vaccine prior to the completion of the study.
  8. Who had received any vaccines within 14 days (for inactivated vaccines) or 28 days (for ) prior to enrollment in this study or who were planning to receive any vaccine within 30 days from the study vaccines.

    (Exception: Influenza vaccine might be administered up to 15 days prior to study vaccination and at least 15 days after study vaccination).

  9. Who had experienced within the 7 days prior to enrollment significant acute infection (for example requiring systemic antibiotic treatment or antiviral therapy) or had experienced fever (defined as body temperature ≥ 38°C) within 3 days prior to enrollment.
  10. Who had any serious acute, chronic or progressive disease (e.g., any history of neoplasm, cancer, diabetes, cardiac disease, disease, (HIV) infection or acquired immunodeficiency syndrome (AIDS), or blood dyscrasias, with signs of cardiac or renal failure or severe malnutrition). Who had epilepsy or any progressive neurological disease or history of Guillain-Barre syndrome.
  11. Who had a history of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine components including diphtheria toxin (CRM-197) and latex in the syringe.
  12. Who had a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from (for example):

    • receipt of therapy within 30 days prior to enrollment (any systemic administered for more than 5 days, or in a daily dose > 1 mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or cancer chemotherapy)
    • receipt of immunostimulants
    • receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 90 days prior to enrollment and for the full length of the study
  13. Who were known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
198 participants (actual)

Study arms

  • Experimental
    MenACWY-CRM

    MenACWY-CRM

    Biological: MenACWY-CRM

Interventions

  • BiologicalMenACWY-CRM

    1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection

06

What researchers measure

Primary outcomes

  1. Percentages of Overall Subjects With Seroresponse After MenACWY-CRM Vaccination

    Immunogenicity was measured as the percentages of overall subjects with hSBA (human serum bactericidal assay) seroresponse, directed against Neisseria meningitidis (N meningitidis) serogroups A, C, W and Y, 28 days after one vaccination of MenACWY-CRM (day 29). The seroresponse is defined as the percentages of subjects achieving hSBA ≥1:8 postvaccination with a prevaccination hSBA \<1:4 and the percentages of subjects achieving at least four-fold increases in postvaccination hSBA from day 1 in subjects with a baseline hSBA ≥1:4

    Time frame: Day 29

Secondary outcomes

  1. Percentages of Subjects With Seroresponse After MenACWY-CRM Vaccination, by Age Group

    Immunogenicity was measured as the percentages of subjects stratified by age group with hSBA response, directed against N meningitidis serogroups A, C, W and Y, 28 days after one vaccination of MenACWY-CRM

    Time frame: Day 29

  2. Geometric Mean Titers (GMTs) of Subjects at Baseline and After MenACWY-CRM Vaccination

    Immunogenicity was measured as hSBA GMTs, against N meningitidis serogroups A, C, W and Y, at baseline (day 1) and 28 days after MenACWY-CRM vaccination (day 29), overall and by age group

    Time frame: Days 1 and 29

  3. Percentages of Subjects With hSBA Titer ≥1:8 at Baseline and After MenACWY-CRM Vaccination

    Immunogenicity was measured as the percentages of subjects with hSBA titer ≥1:8, at baseline (day 1) and 28 days after MenACWY-CRM vaccination (day 29), overall and by age group

    Time frame: Days 1 and 29

  4. Percentages of Subjects Aged 2 Through 5 Years With Solicited Local and Systemic AEs After MenACWY-CRM Vaccination

    Safety was assessed as the percentages of subjects aged 2 through 5 years who reported solicited local and systemic AEs within days 1 through 7 after MenACWY-CRM vaccination

    Time frame: Within days 1 through 7 postvaccination

  5. Percentages of Subjects Aged ≥6 Years With Solicited Local and Systemic AEs After MenACWY-CRM Vaccination

    Safety was assessed as the percentages of subjects aged ≥6 years who reported solicited local and systemic AEs within days 1 through 7 after MenACWY-CRM vaccination, overall and by age group

    Time frame: Within days 1 through 7 postvaccination

  6. Percentages of Subjects Reporting Unsolicited Adverse Events (AEs) After MenACWY-CRM Vaccination

    Safety was assessed in terms of percentages of subjects who reported all the adverse events (AEs) occurring from day 1 through 7, medically attended AEs, SAEs and AEs resulting in premature withdrawal, from day 1 through 29, after MenACWY-CRM vaccination, overall and by age group

    Time frame: AEs occurring from day 1 through 7, medically attended AEs, SAEs and AEs resulting in premature withdrawal, from day 1 through 29

07

Results

Posted Mar 18, 2014

Participant flow

Subjects were enrolled at 5 centers in Russia

Participant flow — Overall Study
Milestone≥2 to ≤10 Years≥11 to ≤17 Years≥18 Years
Started666666
Completed656666
Not completed100
Withdrew: Withdrawal by subject100

Outcome measures

PrimaryPercentages of Overall Subjects With Seroresponse After MenACWY-CRM Vaccination

Immunogenicity was measured as the percentages of overall subjects with hSBA (human serum bactericidal assay) seroresponse, directed against Neisseria meningitidis (N meningitidis) serogroups A, C, W and Y, 28 days after one vaccination of MenACWY-CRM (day 29). The seroresponse is defined as the percentages of subjects achieving hSBA ≥1:8 postvaccination with a prevaccination hSBA \<1:4 and the percentages of subjects achieving at least four-fold increases in postvaccination hSBA from day 1 in subjects with a baseline hSBA ≥1:4

Time frame:
Day 29
Reported as:
Number · Percentage of subjects
Percentages of Overall Subjects With Seroresponse After MenACWY-CRM Vaccination
Percentage of subjectsOverall (≥2 Years)
MenA85 (79 to 90)
MenC74 (67 to 80)
MenW60 (53 to 67)
MenY83 (77 to 88)
SecondaryPercentages of Subjects With Seroresponse After MenACWY-CRM Vaccination, by Age Group

Immunogenicity was measured as the percentages of subjects stratified by age group with hSBA response, directed against N meningitidis serogroups A, C, W and Y, 28 days after one vaccination of MenACWY-CRM

Time frame:
Day 29
Reported as:
Number · Percentage of subjects
Percentages of Subjects With Seroresponse After MenACWY-CRM Vaccination, by Age Group
Percentage of subjects≥2 to ≤10 Years≥11 to ≤17 Years≥18 Years
MenA89 (78 to 95)89 (79 to 96)77 (65 to 86)
MenC69 (56 to 80)82 (70 to 90)71 (58 to 81)
MenW73 (60 to 83)51 (38 to 63)57 (44 to 69)
MenY77 (65 to 87)88 (77 to 95)85 (74 to 92)
SecondaryGeometric Mean Titers (GMTs) of Subjects at Baseline and After MenACWY-CRM Vaccination

Immunogenicity was measured as hSBA GMTs, against N meningitidis serogroups A, C, W and Y, at baseline (day 1) and 28 days after MenACWY-CRM vaccination (day 29), overall and by age group

Time frame:
Days 1 and 29
Reported as:
Geometric mean · human serum bactericidal assay titer
Geometric Mean Titers (GMTs) of Subjects at Baseline and After MenACWY-CRM Vaccination
human serum bactericidal assay titerOverall (≥2 Years)≥2 to ≤10 Years≥11 to ≤17 Years≥18 Years
MenA (Day 1)2.35 (2.17 to 2.55)2.17 (1.79 to 2.62)2.43 (2.01 to 2.93)2.61 (2.11 to 3.23)
MenA (Day 29)93 (73 to 119)67 (38 to 119)134 (77 to 233)76 (41 to 143)
MenC (Day 1)4.07 (3.45 to 4.8)3.16 (2.18 to 4.57)3.59 (2.5 to 5.15)6.68 (4.43 to 10)
MenC (Day 29)59 (43 to 81)28 (14 to 56)47 (24 to 92)112 (52 to 243)
MenW (Day 1)12 (9.42 to 15)7.93 (4.69 to 13)21 (13 to 36)13 (7.16 to 23)
MenW (Day 29)111 (89 to 139)94 (56 to 155)117 (72 to 191)143 (83 to 248)
MenY (Day 1)2.93 (2.61 to 3.28)3.02 (2.33 to 3.92)3.73 (2.89 to 4.82)2.74 (2.05 to 3.66)
MenY (Day 29)58 (46 to 74)32 (18 to 56)67 (39 to 115)80 (43 to 147)
SecondaryPercentages of Subjects With hSBA Titer ≥1:8 at Baseline and After MenACWY-CRM Vaccination

Immunogenicity was measured as the percentages of subjects with hSBA titer ≥1:8, at baseline (day 1) and 28 days after MenACWY-CRM vaccination (day 29), overall and by age group

Time frame:
Days 1 and 29
Reported as:
Number · Percentage of Subjects
Percentages of Subjects With hSBA Titer ≥1:8 at Baseline and After MenACWY-CRM Vaccination
Percentage of SubjectsOverall (≥2 Years)≥2 to ≤10 Years≥11 to ≤17 Years≥18 Years
MenA (Day 1)6 (3 to 10)2 (0.04 to 9)5 (1 to 13)11 (4 to 21)
MenA (Day 29)89 (83 to 93)89 (78 to 95)92 (83 to 97)85 (74 to 92)
MenC (Day 1)26 (20 to 33)13 (6 to 23)17 (9 to 28)49 (37 to 62)
MenC (Day 29)84 (78 to 89)76 (63 to 86)86 (75 to 93)89 (79 to 96)
MenW (Day 1)57 (50 to 64)30 (19 to 43)71 (58 to 81)69 (57 to 80)
MenW (Day 29)97 (93 to 99)95 (87 to 99)98 (92 to 100)97 (89 to 100)
MenY (Day 1)16 (11 to 22)10 (4 to 20)15 (8 to 26)22 (12 to 33)
MenY (Day 29)88 (82 to 92)79 (67 to 88)94 (85 to 98)89 (79 to 96)
SecondaryPercentages of Subjects Aged 2 Through 5 Years With Solicited Local and Systemic AEs After MenACWY-CRM Vaccination

Safety was assessed as the percentages of subjects aged 2 through 5 years who reported solicited local and systemic AEs within days 1 through 7 after MenACWY-CRM vaccination

Time frame:
Within days 1 through 7 postvaccination
Reported as:
Number · Percentage of subjects
Percentages of Subjects Aged 2 Through 5 Years With Solicited Local and Systemic AEs After MenACWY-CRM Vaccination
Percentage of subjects≥2 to ≤5 Years≥2 to ≤3 Years
Tenderness4139
Erythema2628
Induration1917
Change in Eating Habits46
Sleepiness3328
Irritability2617
Vomiting40
Diarrhea1111
Rash46
Fever (≥38 °C)46
Use of analgesics/antipyretics70
SecondaryPercentages of Subjects Aged ≥6 Years With Solicited Local and Systemic AEs After MenACWY-CRM Vaccination

Safety was assessed as the percentages of subjects aged ≥6 years who reported solicited local and systemic AEs within days 1 through 7 after MenACWY-CRM vaccination, overall and by age group

Time frame:
Within days 1 through 7 postvaccination
Reported as:
Number · Percentage of Subjects
Percentages of Subjects Aged ≥6 Years With Solicited Local and Systemic AEs After MenACWY-CRM Vaccination
Percentage of SubjectsOverall (≥6 Years)≥6 to ≤10 Years≥11 to ≤17 Years≥18 Years
Pain48425050
Erythema18181817
Induration14111712
Chills98812
Nausea83118
Malaise20162320
Myalgia19132914
Arthralgia931111
Headache25182727
Rash2305
Fever (≥38 °C)3532
Use of analgesic/antipyretics111899
SecondaryPercentages of Subjects Reporting Unsolicited Adverse Events (AEs) After MenACWY-CRM Vaccination

Safety was assessed in terms of percentages of subjects who reported all the adverse events (AEs) occurring from day 1 through 7, medically attended AEs, SAEs and AEs resulting in premature withdrawal, from day 1 through 29, after MenACWY-CRM vaccination, overall and by age group

Time frame:
AEs occurring from day 1 through 7, medically attended AEs, SAEs and AEs resulting in premature withdrawal, from day 1 through 29
Reported as:
Number · percentage of subjects
Percentages of Subjects Reporting Unsolicited Adverse Events (AEs) After MenACWY-CRM Vaccination
percentage of subjectsOverall (≥2 Years)≥2 to ≤10 Years≥11 to ≤17 Years≥18 Years
Any AEs(days 1 through 7)17201218
At least possibly related AEs (days 1 through 7)103918
SAE(days 1 through 29)0000
At least possibly related SAE(days 1 through 29)0000
Medically attended AE(days 1 through 29)4823
Premature withdrawal due to AE(days 1 through 29)0000

Adverse events

Collected over From day 1 through day 29. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
≥2 to ≤10 Years—0/65 (0%)42/65 (64.6%)
≥11 to ≤17 Years—0/66 (0%)42/66 (63.6%)
≥18 Years—0/66 (0%)44/66 (66.7%)
Overall (≥2 Years)—0/197 (0%)128/197 (65%)
Most frequent other events
Showing 10 of 12
Most frequent other events
Event≥2 to ≤10 Years≥11 to ≤17 Years≥18 YearsOverall (≥2 Years)
Injection site painGeneral disorders27/6533/6633/6693/197
MyalgiaMusculoskeletal and connective tissue disorders5/6519/669/6633/197
HeadacheNervous system disorders8/6518/6618/6644/197
MalaiseGeneral disorders6/6515/6613/6634/197
Injection site erythemaGeneral disorders12/6513/6610/6635/197
Injection site indurationGeneral disorders8/6511/668/6627/197
SomnolenceNervous system disorders9/651/660/6610/197
ChillsGeneral disorders3/655/668/6616/197
IrritabilityGeneral disorders7/650/660/667/197
NauseaGastrointestinal disorders1/657/665/6613/197

Baseline characteristics

Age, Continuous
Age, Continuous(year)≥2 to ≤10 Years≥11 to ≤17 Years≥18 YearsTotal
Mean6.0 ± 2.713.8 ± 2.138.8 ± 12.519.6 ± 15.9
Sex: Female, Male
Sex: Female, Male(Participants)≥2 to ≤10 Years≥11 to ≤17 Years≥18 YearsTotal
FEMALE352944108
MALE31372290
08

Study locations

4 sites
  • Federal State Budgetary Institution 'State Scientific Center 'Institution of Immunology' of the Russian Federal Biomedical Agency'
    Kashirskoye Highway, Moscow 115478, Russian Federation
  • Institution of the Russian Academy of Sciences "Scientific Center for Children Health RAMS"
    Lomonosovskiy Avenue, Moscow 119991, Russian Federation
  • Federal Budgetary Institution of Science 'St-Petersburg Scientific-Research Institution of Epidemiology and Microbiology by name of Pasteur'
    Mira Street, St-Petersburg 197101, Russian Federation
  • Federal State Institution 'Scientific-Research Institution of Children's Infections of the Russian Federal Biomedical Agency'
    Prof.Popova Street, St-Petersburg 197022, Russian Federation
09

References and documents

Publications

  • Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004 Jul 24-30;364(9431):365-7. doi: 10.1016/S0140-6736(04)16725-1. PubMed 15276396 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2012
First posted
Nov 12, 2012
Start
Nov 2012
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Mar 18, 2014
Last update
Apr 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01725217
Lead sponsor
Novartis Vaccines
Responsible party
Sponsor
First posted
Nov 12, 2012
Start date
Nov 2012
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Mar 18, 2014
Last update
Apr 28, 2023

Study contacts

Novartis Vaccines and Diagnostics
study chair · Novartis Vaccines

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion